June 1, 2014, TheScientist publishes their profile of Bruce Ames. Dr. Ames has been conducting research since 1964. He is not one to shy away from controversy, he has pitted himself against industry groups, environmentalists, and his peers through his work identifying DNA mutagens. And he’s not done yet.
According to the National Institutes of Health, cardiovascular disease is the leading cause of death in the United States. For decades, diagnosing the risk for cardiovascular disease has included blood tests for cholesterol, which can be a major cause of cardiovascular disease. Current blood tests measure the levels of low-density lipoprotein (LDL) cholesterol—the “bad” cholesterol—and high-density lipoprotein (HDL)—the “good” cholesterol.
In general, it is assumed that the lower your LDL level, the lower your risk; with HDL, the higher the level, the lower your risk.
A research project developed by Michael Oda, PhD, an Associate Staff Scientist at CHORI is turning part of that assumption on its head. His research also has led to development of a new diagnostic test that more accurately identifies people at risk for cardiovascular disease. “Current testing is based on the notion that the quantity of HDL cholesterol is representative of our risk for cardiovascular disease,” Dr. Oda explains. “We have determined, however, that the quality of HDL—how well it performs its functions—is more important than the quantity in assessing our risk for cardiovascular disease. Simply increasing HDL cholesterol levels in the blood is not sufficient to reduce the risk of heart disease. Click here for a PDF of the above announcement.
May 20, 2014 – CHORI Senior Scientist Dan Granoff, MD, Director of CHORI’s Center for Immunobiology and Vaccine Research, and recipient of the Clorox Endowed Chair has been named the 2014 Maurice Hilleman/Merck Award Laureate by the American Society for Microbiology (ASM). Granoff is being recognized for his work on development of vaccines against serogroup B meningococcus, which causes severe infections of the bloodstream (sepsis) and membranes covering the brain (meningitis). Granoff also played a central role in conceiving a project to develop an affordable serogroup A meningococcal conjugate vaccine for Africa, which has had enormous public health benefit. He will receive the award May 17th in Boston at ASM’s annual meeting, and perform the Hilleman/Merck lecture.
The Maurice Hilleman/Merck Award is ASM’s premier award for major contributions to pathogenesis, vaccine discovery, vaccine development, and/or control of vaccine-preventable diseases. The award is presented in memory of Maurice R. Hilleman, whose work in the development of vaccines has saved the lives of many throughout the world. Click here for a PDF of the above announcement.
Monday, September 11, 2017 2:06 PM